Sector Study: Healthcare Vs. Technology Dividend Dogs, Which To Buy?

Actionable Conclusions (1-5): Brokers Predicted 26.35% To 53.85% Net Gains From Top Five Healthcare Sector Dogs By April 2020
One of five top dividend-yielding Healthcare dogs was verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (It is tinted gray in the chart below). So, our April 23 yield-based forecast for Healthcare dogs, as graded by Wall St. wizards, was 20% accurate.


Projections based on estimated dividend returns from $1000 invested in the five highest yielding stocks and their aggregate one-year analyst median target prices, as reported by YCharts, created the 2019-20 data points. Note: one-year target prices by lone analysts were not applied. Top five probable profit-generating trades projected to April 23, 2020, were:
Takeda Pharmaceutical Co. (TAK) netted $538.48 based on the median of target price estimates from two analysts, plus dividends, less broker fees. The Beta number showed this estimate subject to risk 28% less than the market as a whole.
CVS Health (CVS) was projected to net $399.98, based on the median of target estimates from twenty-seven analysts, plus dividends, less broker fees. The Beta number showed this estimate subject to risk 6% less than the market as a whole.
Bristol-Myers Squibb Co. (BMY) was projected to net $315.85, based on dividends, plus the median of target price estimates from thirteen analysts, less broker fees. The Beta number showed this estimate... Read more